It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.
The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.
Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.
Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.
Emerging therapies in myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, and myelofibrosis could have the potential to shake up the landscape.
Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin to improve outcomes for these patients.
The FDA has lifted its clinical hold on trials exploring pacritinib, according to CTI BioPharma, the developer of the JAK2/FLT3 inhibitor.
A combination regimen of the BCL-2 inhibitor venetoclax plus low-dose cytarabine demonstrated an acceptable safety and pharmacokinetic profile in elderly patients with treatment-naïve acute myeloid leukemia.
In the treatment paradigm of chronic lymphocytic leukemia, anti-CD20 antibodies such as obinutuzumab, and other targeted agents like ibrutinib, have shown promising efficacy and tolerability when compared with standard chemoimmunotherapy.
Novel therapies are being investigated in 2 areas of hematologic malignancies, but the first-line setting is where the brunt of research needs to be conducted.